Johnson & Johnson (NYSE:JNJ) Shares Bought by Bowman & Co S.C.

Bowman & Co S.C. grew its stake in shares of Johnson & Johnson (NYSE:JNJ) by 17.9% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 11,135 shares of the company’s stock after acquiring an additional 1,689 shares during the period. Bowman & Co S.C.’s holdings in Johnson & Johnson were worth $1,846,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently modified their holdings of the company. WealthTrak Capital Management LLC acquired a new stake in shares of Johnson & Johnson during the 4th quarter valued at approximately $26,000. Mountain Hill Investment Partners Corp. acquired a new stake in shares of Johnson & Johnson during the 4th quarter valued at approximately $29,000. Bay Harbor Wealth Management LLC acquired a new stake in shares of Johnson & Johnson during the 4th quarter valued at approximately $32,000. Conquis Financial LLC purchased a new position in shares of Johnson & Johnson during the 4th quarter worth approximately $33,000. Finally, Bernard Wealth Management Corp. purchased a new position in shares of Johnson & Johnson during the 4th quarter worth approximately $36,000. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of brokerages have recently weighed in on JNJ. The Goldman Sachs Group raised shares of Johnson & Johnson from a “neutral” rating to a “buy” rating and raised their price objective for the stock from $157.00 to $172.00 in a research note on Wednesday, April 9th. Guggenheim reissued a “neutral” rating on shares of Johnson & Johnson in a research note on Wednesday, April 2nd. Raymond James dropped their price objective on shares of Johnson & Johnson from $165.00 to $162.00 and set an “outperform” rating for the company in a research note on Monday, April 14th. Sanford C. Bernstein reissued a “market perform” rating on shares of Johnson & Johnson in a research note on Wednesday, April 16th. Finally, Royal Bank of Canada reissued an “outperform” rating and set a $181.00 price objective on shares of Johnson & Johnson in a research note on Wednesday, April 16th. Eleven research analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $170.88.

Johnson & Johnson Stock Up 0.9%

JNJ stock opened at $154.99 on Friday. The stock has a market capitalization of $372.92 billion, a P/E ratio of 23.31, a PEG ratio of 2.56 and a beta of 0.42. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.86 and a current ratio of 1.11. Johnson & Johnson has a one year low of $140.68 and a one year high of $169.99. The company has a 50 day moving average price of $154.31 and a two-hundred day moving average price of $153.65.

Johnson & Johnson (NYSE:JNJ) last released its earnings results on Tuesday, April 15th. The company reported $2.77 EPS for the quarter, topping the consensus estimate of $2.59 by $0.18. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.24%. The firm had revenue of $21.89 billion during the quarter, compared to analysts’ expectations of $21.65 billion. As a group, sell-side analysts expect that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 10th. Stockholders of record on Tuesday, May 27th will be paid a dividend of $1.30 per share. The ex-dividend date of this dividend is Tuesday, May 27th. This is a boost from Johnson & Johnson’s previous quarterly dividend of $1.24. This represents a $5.20 annualized dividend and a dividend yield of 3.36%. Johnson & Johnson’s payout ratio is currently 57.84%.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.